Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies Publisher Pubmed

Salarinia R^{1, 2} ; Sahebkar A³ ; Peyvandi M^{4, 5} ; Mirzaei HR⁶ ; Jaafari MR⁷ ; Riahi MM¹ ; Ebrahimnejad H⁸ ; Nahand JS¹ ; Hadjati J⁹ ; Asrami MO¹⁰ ; Fadaei S¹¹ ; Salehi R¹² ; Mirzaei H¹

Show Affiliations

1. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Department of Medical Biotechnology, School of Medicine, North khorasan University of Medical Sciences, Bojnourd, Iran
3. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Anatomical Sciences, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5. Department of Anatomical Sciences, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
7. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
8. Department of Oral and Maxillofacial Radiology, Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran
9. Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
10. Department of Cellular and Molecular Biotechnology, Islamic Azad University of Tonekabon, Mazandaran, Iran
11. Student Research Committee, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
12. Department of Medical Genetics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Current Cancer Drug Targets Published:2016

Abstract

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents. © 2016 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Reciprocal Interconnection of Mirnome-Epigenome in Cancer Pathogenesis and Its Therapeutic Potential, Epigenetics Territory and Cancer (2015)

2. Sirna and Epigenetic Aberrations in Ovarian Cancer, Journal of Cancer Research and Therapeutics (2016)

3. Methylation in Colorectal Cancer, Epigenetics Territory and Cancer (2015)

4. Regulation of Dna Methylation Machinery by Epi-Mirnas in Human Cancer: Emerging New Targets in Cancer Therapy, Cancer Gene Therapy (2021)

5. The Role of Dna Methylation in Cancer, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)

6. Arsenic Trioxide Alters the Microrna Expression Profile of U87 Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry (2016)

7. New Methods in the Diagnosis of Cancer and Gene Therapy of Cancer Based on Nanoparticles, Cancer Gene Therapy (2017)

8. Promotor Methylation in Ocular Surface Squamous Neoplasia Development: Epigenetics Implications in Molecular Diagnosis, Expert Review of Molecular Diagnostics (2023)

Experts (# of related papers)

View all Related Experts

Seyed Hamidollah Ghaffari (4)

Pantea Izadi (2)

Other Related Docs

9. Advances in Epigenetic Treatment of Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review, Clinical Epigenetics (2025)

10. Cancer Genetics at a Glance: The Comprehensive Insights, Cancer Genetics and Psychotherapy (2017)

11. Dna Methyltransferase Activity Detection Based on Graphene Quantum Dots Using Fluorescence and Fluorescence Anisotropy, Sensors and Actuators# B: Chemical (2017)

12. Multiple Functions of P27 in Cell Cycle, Apoptosis, Epigenetic Modification and Transcriptional Regulation for the Control of Cell Growth: A Double-Edged Sword Protein, DNA Repair (2018)

13. Epigenetic Targeting of Cancer Stem Cells by Polyphenols (Cancer Stem Cells Targeting), Phytotherapy Research (2021)

14. Microrna As a Systemic Intervention in the Specific Breast Cancer Subtypes With C-Myc Impacts; Introducing Subtype-Based Appraisal Tool, Journal of Cellular Physiology (2018)

15. Hypermethylated Mir-424 in Colorectal Cancer Subsequently Upregulates Vegf, Journal of Gastrointestinal Cancer (2022)

16. Micrornas As Biomarkers for Early Diagnosis, Targeting and Prognosis of Prostate Cancer, Pathology Research and Practice (2023)

17. Mir-377 Reverses Cancerous Phenotypes of Pancreatic Cells Via Suppressing Dnmt1 and Demethylating Tumor Suppressor Genes, Epigenomics (2017)

18. Differential Role of Micrornas in Prognosis, Diagnosis, and Therapy of Ovarian Cancer, Biomedicine and Pharmacotherapy (2016)

19. An Introduction to Expression and Regulation of Testicular Cancer Antigens: Review Article, Tehran University Medical Journal (2018)

20. Epigenetic of Retinoic Acid Receptor ß2 Gene in Breast Cancer, Epigenetics Territory and Cancer (2015)

21. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review, Cancers (2023)

22. Epigenetics and Three Main Clinical Aspects of Breast Cancer Management, Epigenetics Territory and Cancer (2015)

23. Epigenetic Regulation of Specific Transcription Factors in Osteogenic Differentiation of Mesenchymal Stem Cells, Turkish Journal of Biology (2016)

24. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers, Immunological Investigations (2016)

25. Duchenne Muscular Dystrophy: An Updated Review of Common Available Therapies, International Journal of Neuroscience (2018)

26. Epigenetic Drugs As New Emerging Therapeutics: What Is the Scale's Orientation of Application and Challenges?, Pathology Research and Practice (2023)

27. A Comparative Study Based on Docking and Molecular Dynamics Simulations Over Hdac-Tubulin Dual Inhibitors, Journal of Molecular Graphics and Modelling (2016)

28. Targeting Epigenetics in Cancer: Therapeutic Potential of Flavonoids, Critical Reviews in Food Science and Nutrition (2021)

29. Epigenetic-Based Cancer Therapeutics: New Potential Hdac8 Inhibitors, Journal of Biomolecular Structure and Dynamics (2022)

30. Environmental Toxicants, Incidence of Degenerative Diseases, and Therapies From the Epigenetic Point of View, Archives of Toxicology (2017)

31. Demethylation and Alterations in the Expression Level of the Cell Cycle–Related Genes As Possible Mechanisms in Arsenic Trioxide–Induced Cell Cycle Arrest in Human Breast Cancer Cells, Tumor Biology (2017)

32. The Association of Mir-Let 7B and Mir-548 With Pten in Prostate Cancer, Urology Journal (2019)

33. Cpg Islands Hypermethylatioin the Promoter Region of Gstp1 Gene in Cell-Free Dna As a Noninvasive Biomarker for Detecting Prostate Cancer, Biochemical and Cellular Archives (2016)

34. Future Challenges and Prospects for the Epigenetics of Autoimmunity, The Epigenetics of Autoimmunity (2018)

35. Genetic and Epigenetic of Medullary Thyroid Cancer, Iranian Biomedical Journal (2018)

36. The Gene Expression Profile and Dna Methylation Pattern of Cdh1 and Dnmt1 Genes in Acute Promyelocytic Leukemia (Apl), Reports of Biochemistry and Molecular Biology (2020)

37. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)

38. Piwi-Interacting Rnas: New Biomarkers for Diagnosis and Treatment of Breast Cancer, Cell and Bioscience (2020)

39. Study on the Interaction of the Cpg Alternating Dna With Cdte Quantum Dots, Journal of Fluorescence (2017)

40. Novel Treatment Opportunities for Sulfur Mustard-Related Cancers: Genetic and Epigenetic Perspectives, Archives of Toxicology (2017)

41. Contributory Role of Micrornas in Anti-Cancer Effects of Small Molecule Inhibitor of Telomerase (Bibr1532) on Acute Promyelocytic Leukemia Cell Line, European Journal of Pharmacology (2019)

42. Pharmacoepigenetics of Immunological Disorders, Pharmacoepigenetics (2019)

43. A Systematic Review and Meta-Analysis of the Dna Methylation in Colorectal Cancer Among Iranian Population, Gene Reports (2021)

44. The Role of Oncomirs in the Pathogenesis and Treatment of Breast Cancer, Biomedicine and Pharmacotherapy (2016)

Style	Citing Format
MLA	Salarinia R, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets, vol. 16, no. 9, 2016, pp. 773-788.
APA	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, Nahand JS, Hadjati J, Asrami MO, Fadaei S, Salehi R, Mirzaei H (2016). Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets, 16(9), 773-788.
Chicago	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets 16, no. 9 (2016): 773-788.
Harvard	Salarinia R et al. (2016) 'Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies', Current Cancer Drug Targets, 16(9), pp. 773-788.
Vancouver	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, et al.. Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets. 2016;16(9):773-788.
BibTex	@article{ author = {Salarinia R and Sahebkar A and Peyvandi M and Mirzaei HR and Jaafari MR and Riahi MM and Ebrahimnejad H and Nahand JS and Hadjati J and Asrami MO and Fadaei S and Salehi R and Mirzaei H}, title = {Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies}, journal = {Current Cancer Drug Targets}, volume = {16}, number = {9}, pages = {773-788}, year = {2016} }
RIS	TY - JOUR AU - Salarinia R AU - Sahebkar A AU - Peyvandi M AU - Mirzaei HR AU - Jaafari MR AU - Riahi MM AU - Ebrahimnejad H AU - Nahand JS AU - Hadjati J AU - Asrami MO AU - Fadaei S AU - Salehi R AU - Mirzaei H TI - Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies JO - Current Cancer Drug Targets VL - 16 IS - 9 SP - 773 EP - 788 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract